Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M678Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M1.4EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)15.7Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book1.510-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %3.8PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M46,450,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PID

Number of guru portfolios checked: 68.
No Entry found in the selected group of Gurus. You can

PID is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


PID: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Element, MartynDirector 2016-08-08Buy10,000$0.159633.33view
Finch, S. WayneDirector, Senior Officer 2016-08-08Sell200$12.120.66view
Finch, S. WayneDirector, Senior Officer 2016-08-08Sell1,800$12.120.66view
Finch, S. WayneDirector, Senior Officer 2016-08-08Sell2,000$12.1120.56view
Ghuldu, RishiSenior Officer 2016-08-08Sell149$23.45-37.74view
Louis, PeterSenior Officer 2016-08-08Sell5,000$87.86-83.38view
Omni-Lite Industries Canada InIssuer 2016-08-08Buy5,000$1.7758.82view
Omni-Lite Industries Canada InIssuer 2016-08-08Buy4,700$1.65784.85view
Kovacevic, John GianniDirector, Senior Officer 2016-08-08Buy200,000$0.0818150view
Espaillat Lamarche, Julio ErneSenior Officer 2016-08-08Sell190,000$0.62333.33view

Quarterly/Annual Reports about PID:

    News about PID:

    Articles On GuruFocus.com
    Searching The World For The Best Dividend Stocks Jan 06 2015 

    More From Other Websites
    Teva Pharmaceutical: A Successful Bond Financing Program in 2016 Aug 22 2016
    How Merial Contributes to Sanofi’s Growth Aug 22 2016
    What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16? Aug 19 2016
    Behind Sanofi’s Diabetes and Cardiovascular Performance in 2Q16 Aug 18 2016
    Genzyme Continued to Boost Growth for Sanofi in 2Q16 Aug 18 2016
    Inside Sanofi’s Valuation Changes Aug 17 2016
    How Did Novo Nordisk Perform across Geographies in 1H16? Aug 09 2016
    A New Low Volatile International ETF for Dividend Lovers Aug 08 2016
    A New Low Volatility International ETF for Dividend Lovers Aug 08 2016
    An Update on Shire’s Upcoming Milestones Aug 05 2016
    How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16? Aug 02 2016
    How Much Growth Will Novo See in 2Q16? Aug 01 2016
    GlaxoSmithKline Increases Top Line in 2Q16 Jul 30 2016
    What to Expect from Shire’s Genetic Disease Franchise Jul 28 2016
    What Role Did Innovative Medicines Play in Novartis’s 2Q16 Earnings? Jul 22 2016
    How Did Novartis’s 2Q16 Earnings Stand up to Analyst Estimates? Jul 21 2016
    Novartis’s 2Q16 Earnings: What’s Expected? Jul 18 2016
    How Could the Novartis-Xencor Alliance Benefit Novartis? Jul 01 2016
    What Is Xencor’s XmAb Technology? Jun 30 2016
    A New Idea Among International Dividend ETFs Jun 30 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)